Development of Autoimmunity in IL-14alpha-transgenic Mice
Overview
Authors
Affiliations
Multiple genetic loci contribute to the development of systemic lupus erythematosus (SLE). In murine models for SLE, various genes on chromosome four have been implicated. IL-14 is a cytokine originally identified as a B cell growth factor. The il14 gene is located on chromosome 4. IL-14alpha is a cytokine encoded by the plus strand of the IL-14 gene using exons 3-10. The expression of IL-14alpha is increased in (NZB x NZW)F1 mice. In this study, we produced IL-14alpha-transgenic mice to study the role of IL-14alpha in the development of autoimmunity. At age 3-9 mo, IL-14alpha-transgenic mice demonstrate increased numbers of B1 cells in the peritoneum, increased serum IgM, IgG, and IgG 2a and show enhanced responses to T-dependent and T-independent Ags compared with littermate controls. At age 9-17 mo, IL-14alpha-transgenic mice develop autoantibodies, sialadenitis, as in Sjögren's syndrome, and immune complex-mediated nephritis, as in World Health Organization class II SLE nephritis. Between the ages 14-18 mo, 95% of IL-14alpha-transgenic mice developed CD5+ B cell lymphomas, consistent with the lymphomas seen in elderly patients with Sjögren's syndrome and SLE. These data support a role for IL-14alpha in the development of both autoimmunity and lymphomagenesis. These studies may provide a genetic link between these often related disorders.
Sarkar A, Chakraborty D, Malik S, Mann S, Agnihotri P, Monu M J Inflamm Res. 2024; 17:10027-10045.
PMID: 39634288 PMC: 11615101. DOI: 10.2147/JIR.S465051.
Huang K, Wagner L, Takano T, Lin X, Bagavant H, Deshmukh U Elife. 2024; 13.
PMID: 39259200 PMC: 11390111. DOI: 10.7554/eLife.97069.
Huang K, Wagner L, Takano T, Lin X, Bagavant H, Deshmukh U bioRxiv. 2024; .
PMID: 38562738 PMC: 10983907. DOI: 10.1101/2024.03.19.585719.
Nascimento Da Conceicao V, Sun Y, Chai X, Ambrus J, Mishra B, Singh B J Transl Autoimmun. 2023; 7():100210.
PMID: 37711153 PMC: 10497794. DOI: 10.1016/j.jtauto.2023.100210.
Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer.
Wang B, Chen C, Jiang S, Huang Y, Zeng Y, Li L Clin Med Insights Oncol. 2023; 17:11795549231163369.
PMID: 37101524 PMC: 10123909. DOI: 10.1177/11795549231163369.